[{"orgOrder":0,"company":"Tibotec BVBA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"antibiotics||ATP synthase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tibotec BVBA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tibotec BVBA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tibotec BVBA \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"antibiotics||ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"antibiotics||ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Wits Health Consortium","sponsor":"Regents of the University of California | University of Cape Town | Perinatal HIV Research Unit, Witswatersrand","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wits Health Consortium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wits Health Consortium \/ Regents of the University of California | University of Cape Town | Perinatal HIV Research Unit, Witswatersrand","highestDevelopmentStatusID":"10","companyTruncated":"Wits Health Consortium \/ Regents of the University of California | University of Cape Town | Perinatal HIV Research Unit, Witswatersrand"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res France","sponsor":"Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res France","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res France \/ Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development","highestDevelopmentStatusID":"10","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res France \/ Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res France","sponsor":"Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development | University of San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res France","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res France \/ Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development | University of San Francisco","highestDevelopmentStatusID":"10","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res France \/ Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development | University of San Francisco"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res Netherlands","sponsor":"London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res Netherlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","highestDevelopmentStatusID":"9","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res Netherlands","sponsor":"London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res Netherlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","highestDevelopmentStatusID":"9","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res Netherlands","sponsor":"London School of Hygiene & Tropical Medicine | Ministry of Health, Uzbekistan | Ministry of Public Health, Belarus | THINK TB & HIV Network | University of Liverpool | Wits Health Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res Netherlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | Ministry of Health, Uzbekistan | Ministry of Public Health, Belarus | THINK TB & HIV Network | University of Liverpool | Wits Health Consortium","highestDevelopmentStatusID":"9","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | Ministry of Health, Uzbekistan | Ministry of Public Health, Belarus | THINK TB & HIV Network | University of Liverpool | Wits Health Consortium"},{"orgOrder":0,"company":"University College, London","sponsor":"Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum M\u00fcnchen | KNCV Tuberculosis Found","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum M\u00fcnchen | KNCV Tuberculosis Found","highestDevelopmentStatusID":"8","companyTruncated":"University College, London \/ Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum M\u00fcnchen | KNCV Tuberculosis Found"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)","highestDevelopmentStatusID":"8","companyTruncated":"Brigham and Women's Hospital \/ University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"OPC-167832","moa":"||Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OPC-167832","moa":"||Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"OPC-167832","moa":"||Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bill & Melinda Gates Foundation \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ GSK"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Delamanid","moa":"||Mycobacterium tuberculosis H37Rv","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Pretomanid","moa":"||mycolic acid inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Lupin Ltd"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Pretomanid","moa":"||mycolic acid inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Bedaquiline
Details :
Bedaquiline is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Tuberculosis.
Details :
Sirturo (bedaquiline) is an approved ATP synthase inhibitor. It is given orally for the treatment in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Details :
OPC-167832 (quabodepistat) is a potent and orally active dprE1 inhibitor, which is being evaluated in combination with delamanid & bedaquiline for the treatment of pulmonary tuberculosis.
Details :
Sirturo (bedaquiline) is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary MDR-TB.
Sponsor :
Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum München | KNCV Tuberculosis Found
Details :
Bedaquiline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis, Pulmonary.
Sponsor :
Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum München | KNCV Tuberculosis Found
Details :
This program is evaluating two novel drug regimens comprising five antibacterial agents—bedaquiline, delamanid, pretomanid, quabodepistat (formerly known as OPC-167832), and sutezolid.
Sponsor :
University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)
Details :
Bedaquiline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tuberculosis, Pulmonary.
Sponsor :
University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)
Details :
The PAN-TB collaboration is a first-of-its-kind effort to accelerate development of a drug regimen capable of treating all forms of TB, and identifying promising regimens for further development including OPC-167832.
Details :
Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Details :
The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Reset All
